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(range 2.86 to 12.3 x 106). No patient died within 100 days of
transplant. The median follow up was 27 months (range 1.5
to 79.8). The median overall survival at 1 year, 3 years, and 5
years was 87%, 77%, and 77%. Relapse free survival at 1 year, 3
years, and 5 years was 78%, 68%, and 68%.
In conclusion, bortezomib-based therapy followed by
ASCT is well tolerated and can be performed with low TRM,
resulting in durable OS and RFS.148
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Background: While various peripheral blood stem cell
(PBSC) mobilization strategies have been employed, gran-
ulocyte-colony stimulating factor (G-CSF) with or without
plerixafor is widely utilized for its efﬁcacy, safety and cost. To
date, the recombinant G-CSF known as tbo-ﬁlgrastim has not
been compared to traditionally used ﬁlgrastim for mobili-
zation of PBSC or for engraftment after autologous stem cell
transplantation (ASCT). Therefore, we sought to compare the
efﬁcacy and cost of tbo-ﬁlgrastim to ﬁlgrastim during
mobilization and engraftment.
Methods: Patients with lymphoma or plasma cell disor-
ders undergoing G-CSF mobilization, with or without
plerixafor, were included in this retrospective chartTable 1
Patient demongraphics and outcomes*, n ¼ 148
Tbo-ﬁlgrastim Filgrastim P
value
Demographics
Age (years) 56.0 (29.0-72.0) 61.5 (21.0-82.0) 0.016
Gender, male 33 (53.2%) 48 (55.8%) 0.867
Diagnosis 0.472
Plasma cell disorders* 41 (66.1%) 62 (72.1%)
Lymphoma Mobilization 21 (33.9%) 24 (27.9%)
Mobilization
G-CSF(n) 62 86
CD34 Day 4 (cells/mL) 10.5 (0.0-88.0) 12.5 (1.0-65.0) 0.534
Plerxiafor use 45 (72.6%) 60 (69.8%) 0.854
CD34 Day 5 (cells/mL) 5.00 (1.0-292.0) 43 (4.0-174.0) 0.087
CD34 collected days* (x
106 cells/kg)
4.61 (0.12-19.83) 3.78 (0.68-16.34) 0.150
Total collection days (x 106
cells/kg)
1.4 1.6 0.010
CD34 infused (x 106 cells/
kg)
5.90 (0.12-19.83) 5.56 (1.69-16.34) 0.470
Engraftment
G-CSF (n) 70 78
CD34* infused (x 106 cell/
kg)
3.62 (2.24-10.84) 361 (1.70-9.78) 0.447
Transfusion*
Packed red blood cells 1.7 1.7 0.866
Plalelets 1.7 1.4 0.113
Ferbrile neutropenia 48 (68.6%) 53 (67.9%) 0.935
Days to WBC engraftmentz 11.5 11.7 0.251
Days to platelet
engraftmentz
17.7 18.5 0.244
Note: G-CSF - granulocyte colony stimulating factor; WBC - white blood cells
*All values are median unless otherwise speciﬁed.
zPlasma cell disorder includes multiple myeloma; Waldenstrom’s macro-
globulinemia; and amyloidosis.
zValue reported as mean.review. Patients receiving a second autologous transplant
or mobilized with chemotherapy were excluded. Tbo-ﬁl-
grastim and ﬁlgrastim were given at a dose of 10 mcg/kg
daily for four days prior to PBSC collection on day 5. The
adjunct use of plerixafor was determined by circulating
CD34+ cells/mL on day 4 of mobilization. Post-transplant,
each agent was given at a dose of 5 mcg/kg daily on day
+7 and continued until neutrophil engraftment. The pri-
mary outcome was total collected CD34+ cells/kg. Sec-
ondary outcomes included total collection days, peripheral
CD34+ cells/mL on day 4 of mobilization, and the adjunc-
tive use of plerixafor. Post-transplant outcomes included
time to neutrophil engraftment, the number of blood
product transfusions required prior to engraftment, and
events of febrile neutropenia. Cost minimization analysis
was also conducted to determine direct cost-savings be-
tween the two G-CSF products.
Results: A total of 148 patients were included in the ﬁnal
analysis. Median patient age was 60 years, 81 (55%) were
male and 86 (58%) received ﬁlgrastim. Patients in the ﬁl-
grastim group had a higher median age compared to those
receiving tbo-ﬁlgrastim (61.5 vs 56 years, p¼0.01). There
were no other statistically signiﬁcant differences in patient
demographics between the two groups. Patients receiving
ﬁlgrastim collected a median of 5.565 x 106 CD34+ cells/kg
compared to a median of 5.9 x 106 CD34+ cells/kg for the
tbo-ﬁlgrastim group (p¼0.47). There were no statistically
signiﬁcant differences in all secondary endpoints except a
mean fewer days of collection in patients receiving tbo-ﬁl-
grastim (1.4 vs 1.6 days, p¼0.01). Patients receiving tbo-ﬁl-
grastim had a mean cost savings of $761.46 per patient
during mobilization and $353.46 per patient during
engraftment.
Conclusions: Tbo-ﬁlgrastim demonstrated similar CD34+
yield as compared to ﬁlgrastim in the setting of PBSC
collection with no difference in secondary efﬁcacy and
safety outcomes. Furthermore, tbo-ﬁlgrastim utilization was
associated with cost savings of approximately $1,115 per
patient.149
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The incidence of venous thromboembolic events (VTE) after
autologous stem cell transplantation is around 5 percent.
However, in this setting the incidence of cerebral venous
sinus thrombosis (CVST) is unknown. Here we describe the
ﬁrst reported case of CVST after autologous stem cell trans-
plantation in the literature. In our patient CVST greatly
increased the morbidity of post-transplant care.
A 62-year-old female underwent autologous stem cell
transplantation for multiple myeloma, and at the time of
transplant was in complete remission. On D+17, she devel-
oped acute encephalopathy. A non-contrast computerized
tomographic (CT) scan of the head revealed a thin focus of
hyper attenuation along the right tentorium. Magnetic
Resonance Imaging/Venography (MRI/MRV) head and brain
revealed a dural sinus thrombosis involving the entire right
transverse, sigmoid sinus and visible portions of right in-
ternal jugular vein, without venous infarct of the brain. CT
Figure 1. MRI/MRV head and brain with sinus thrombosis involving the right internal jugular vein (A), sigmoid sinus (B) and entire right transverse sigmoid sinus (C).
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extension and speciﬁcally, no clot on the central venous
catheter. Patient was started on anticoagulation after which
her mentation improved gradually over several weeks.
Follow up MRI/MRV after two weeks of anticoagulation
showed persistence of the dural clot, but no extension. The
patient was discharged to the outpatient environment with
continued thrombosis on prolonged therapy and is currently
D+145 from transplant.
Patients undergoing stem cell transplantation (SCT) have
known risk factors for the development of VTE including the
underlying malignancy, chemotherapy regimens, immobility
during hospitalization and the use of central venous cathe-
ters. CVST is an unusual complication following SCT and was
heralded in this case by both dramatic clinical features and
subtle ﬁndings on imaging. It is unclear if CVST is extremely
rare or under-diagnosed post-transplant, and is a possible
element in the differential diagnosis of confusion in this
setting. Once detected, the dural thrombus persisted despite
prolonged anti-coagulation and steady improvement of pa-
tient’s sentinel symptoms.150
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Background: Preliminary data presented by our group at the
2014 ASBMTmeeting suggested a correlation between higher
CD34+ Cell-Dose Infused (CD34-CDI) during ASCTand shorter
time to ALC recovery for MM patients (pts). This updated
analysis which includes additional pts with longer follow-up
supports our prior results, and suggests a correlation between
higher CD34-CDI and decreased incidence of infections.
Methods: From 1/2012-1/2014, 21 consecutive MM pts who
had undergone ASCT were evaluated retrospectively to
determine the impact of CD34-CDI on ALCs and infectious
events. During the ﬁrst 100 days post-ASCT, all infectious
complications were noted and ALCs collected. Overall sur-
vival and progression free survival were monitored. ALC re-
covery was deﬁned as the ﬁrst day of three consecutive
measurements for the cutoff values: ALC  800, ALC  1000,and ALC  1500. Cox proportional hazard models were
applied to evaluate the association of CD34-CDI to ALC re-
covery. The signiﬁcance of the associationwas assessed using
the Log Rank Test since no competing risks were identiﬁed.
Additionally, the Nonparametric Wilcoxon Rank Sum Test
was used to determine the relationship between CD34-CDI
and the development of any infectious events.
Results: Of the 21 patients, 81% were male, 19% were female.
Median age was 62 years (range 45-71). Majority (62%) had
IgG MM and kappa light chain restriction (86%). Approxi-
mately 62% had ISS Stage II/III disease. Patients who had
received a higher CD34-CDI were more likely to achieve ALC
 800 (p¼0.040) and ALC  1000 (p¼0.021). For ALC re-
covery deﬁned as ALC  1500, no statistical signiﬁcance was
observed (p¼0.27). When CD34-CDI was < 4x106 cells/kg,
median times to ALC  800 and ALC  1000 were 33.5 and
41.5 days respectively, and were 19 and 22 days when CD34-
CDI was > 4x106 cells/kg. Pts without infections tended to
have higher CD34-CDI compared to those pts with infections
(p¼0.0452). Five of six pts with CD34-CDI < 4x106 cells/kg,
and three of 15 pts with CD34-CDI > 4x106 cells/kg devel-
oped at least one bacterial infectious complication. Among
pts who received CD34-CDI < 4x106 cells/kg, 60% of in-
fections (9 out of 15 events) occurred. With 17 months (mo)
of median follow-up (range 9-30 mo), ﬁve pts have relapsed
and one death has occurred. Four of ﬁve relapses, and the one
death received CD34-CDI > 4x106 cells/kg.
Conclusion: Higher CD34-CDI (> 4x106 cells/kg) may
shorten time to ALC recovery and limit infectious complica-
tions. Most relapses to date occurred in pts transplanted with
CD34-CDI > 4x106 cells/kg, raising the question of product
contamination with higher cell-doses. Additional follow-up
and larger prospective trials are needed to further deﬁne
optimal CD34-CDI that balances the beneﬁts of shortened
time to ALC recovery, minimizing infectious complications,
and decreasing risk of product contamination.
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